Latest Study on Tysabri

I will admit to being a bit surprised by the number of MS patients I have met who are on Tysabri, considering the incidents of  PML that are associated with the drug. I recognize the improved quality of life associated with the drug, and I’m told it’s efficacy is superior to other disease modifying drugs; but according to my neurologist, the risks do not justify the benefit (and that the scuttlebutt among the medical community is that the risks are worse than officially reported).

The decision, of course, is up to each patient, but it’s important to have the most up to date information in order to make that decision. Here’s the latest from Biogen, the company that manufactures the drug, and it suggests the risk of PML increases the longer one is on Tysabri.

News Detail : National MS Society.

Related articles by Zemanta

• More Doses of Multiple Sclerosis Drug Raise Risk of Brain Infection (nlm.nih.gov)
• More Checks for Biogen’s Tysabri – Analyst Blog (benzinga.com)
• Biogen’s Tysabri to Carry New Warnings, FDA Says (Update1) (businessweek.com)
• Biogen Idec’s Tysabri Continues to Grow in Popularity but Poses Some Risks (seekingalpha.com)
• Biogen, Elan’s Tysabri Drug Linked to 35 Brain Disease Cases (businessweek.com)
• FDA warns of brain risks with frequent Tysabri use (seattletimes.nwsource.com)
• Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore (xconomy.com)
• FDA warns of brain risks with frequent Tysabri use (sfgate.com)

Related posts:

1. Author: Tysabri Doesn’t Look So Deadly Anymore; Me: Looks Deadly Enough
2. New label says Tysabri risks increase over time
3. Biogen reports 6th case of PML in Tysabri patients
4. Mutliple Sclerosis Patients Still Being Asked to "Roll the Dice" on Tysbari
5. Possible Treatment For PML In Tysabri Multiple Sclerosis Partients … – Med…